Investors
Dōsys Health LLC
The founder has built two products: one is available and the other is in evaluation. The company is pre-revenue. Current evidence and funding priorities are outlined below; round size, valuation and terms are discussed directly with qualified investors.
The problem
What the guideline changed.
The 2020 ASHP/IDSA/PIDS/SIDP consensus guideline recommends AUC-guided vancomycin monitoring, preferably with Bayesian estimation, in place of trough-only monitoring. Doing that requires software. The established Bayesian platforms are priced and implemented for large health systems; many community hospitals and individual clinicians are still on trough-based protocols or manual calculation. Adoption figures vary by survey and are not restated here.
What exists
Two products.
Vancomyzer™ — a Bayesian AUC-guided vancomycin calculator for adults, built on the published Colin 2019 population model, used at every adult body size. Live at vancomyzer.com; access is currently free. Its equations are published; its implementation has been checked against published values, synthetic patients and a separately built program. It has not been validated in real patients.
Dōsys Parenteral Nutrition — an evaluation release for synthetic adult cases only. It has not completed independent clinical validation and is not for patient care.
Both are designed to meet the non-device clinical decision support criteria of FD&C Act §520(o)(1)(E); the FDA has made no determination. Neither has EHR integration.
Free access
Vancomyzer free access
Access to Vancomyzer is currently free. Open the calculator
What comes next
In order.
- Independent clinical evaluation of Vancomyzer with de-identified patient data at a participating hospital, with the analysis plan and acceptance criteria written before the data are analyzed.
- Institutional discussions depend on requirements, approvals and agreed scope. Evaluation participation does not create a subscription.
- Independent clinical review of the parenteral nutrition calculator before any clinical release.
No partnerships are claimed here that are not yet signed. Detailed financial modeling, pipeline and unit economics are shared with qualified investors under NDA.
What capital would fund
In order of priority.
- The clinical evaluation study and its publication.
- Regulatory documentation and legal review.
- Engineering for both calculators.
- Hosting, security and compliance work needed for institutional data agreements.
- Operating runway and a first clinical hire.
Who
Founder and sole developer.
Mario Cardenas, PharmD, MBA — ICU clinical pharmacist and pharmacy preceptor in McAllen, Texas; founder and CEO of Dōsys Health LLC. He designed the clinical logic, safety checks and regulatory approach, and wrote the software.